Nuo Therapeutics, Inc.

Equities

AURX

US67059V2097

Biotechnology & Medical Research

Market Closed - OTC Markets 12:21:21 2024-04-25 pm EDT 5-day change 1st Jan Change
0.8 USD 0.00% Intraday chart for Nuo Therapeutics, Inc. 0.00% +45.45%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Exor-backed NUO invests in Italian teenage clothing chain Subdued RE
Nuo Therapeutics, Inc. announced that it has received $0.9625 million in funding CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.9625 million in funding CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
Insider Buy: Nuo Therapeutics MT
Nuo Therapeutics, Inc. announced that it has received $1.035 million in funding CI
Nuo Therapeutics, Inc. announced that it expects to receive $1.035 million in funding CI
Nuo Therapeutics Selects to Exhibit Aurix® System At Vizient Innovative Technology Exchange CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022 CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.5 million in funding from Pacific Medical, Inc. CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022 CI
Nuo Therapeutics, Inc. Enters into an Exclusive Sales Agent and Services Agreement with Pacific Medical, Inc CI
Nuo Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Insider Buy: Nuo Therapeutics MT
Nuo Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021 CI
Nuo Therapeutics, Inc. Auditor Raises 'Going Concern' Doubt CI
Nuo Therapeutics, Inc. announced that it expects to receive $3.55 million in funding CI
Nuo Therapeutics, Inc. Announces Publication of Final Decision Memo for Autologous Blood Derived Products for Chronic Non-Healing Wounds by Centers for Medicare & Medicaid Services CI
Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019 CI
Nuo Therapeutics, Inc. announced that it expects to receive $0.5 million in funding CI
Chart Nuo Therapeutics, Inc.
More charts
Nuo Therapeutics, Inc. is a regenerative therapies company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. Its flagship product, Aurix, is a biodynamic hematogel that uses a patient’s own platelets and plasma as a catalyst for healing. The Company’s commercial offering consists of point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix (the Aurix System), which produces a platelet rich plasma (PRP) gel at the point of care using the patient’s own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
More about the company